Erbitux Approved to Treat Head and Neck Cancers
Fri Mar 3, 11:51 PM ET
The drug, which received FDA approval in 2004 to treat colorectal cancer, may now be used in combination with radiation to treat squamous cell cancer of the head and neck that can't be surgically removed, the Associated Press reported.
The FDA also approved Erbitux for treatment of patients with head and neck cancer whose cancer has spread despite treatment with chemotherapy.
The approval was based on a study that found that a combination of the drug and radiation therapy extended the lives of head and neck cancer patients by 20 months, compared to treatment with radiation alone, the AP reported.
This is the first new drug to treat head and neck cancer since the 1950s. Head and neck cancer includes cancers of the mouth, tongue, larynx and pharynx. About 29,000 Americans are diagnosed with head and neck cancer each year.
The drug is produced by ImClone Systems Inc. and Bristol-Myers Squibb Co.
More information
This FDA page has more about Erbitux.
-
Health - HealthDay
Add headlines to your personalized My Yahoo! page
(About My Yahoo! and RSS)
On Yahoo! Health
Take charge of your health with Cheryl Koch's nutrition blog.
Copyright © 2006 HealthDay.
All rights reserved.
The information contained above is intended
for general reference purposes only. It is not a substitute for professional
medical advice or a medical exam. Always seek the advice of your physician
or other qualified health professional before starting any new treatment.
Medical information changes rapidly and while Yahoo and its content providers
make efforts to update the content on the site, some information may be out of date. No health information on Yahoo, including information about herbal therapies and other dietary supplements, is regulated or evaluated
by the Food and Drug Administration and therefore the information should not be used to diagnose, treat, cure or prevent any disease without the supervision of a medical doctor.